Nemolizumab to target the itch–scratch cycle in paediatric atopic dermatitis
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad319 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Antonia Lloyd-Lavery. Beteiligte Einrichtung: Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Atopic dermatitis (AD)-related pruritus can have a significant negative impact on affected individuals’ quality of life and is associated with sleep and mood disturbance.1,2 Interleukin (IL)-31 plays a key role driving and maintaining the itch–scratch cycle in AD and contributes to inflammation and skin barrier dysfunction.3 Nemolizumab, a humanized monoclonal antibody targeting IL-31, reduces pruritus and improves quality of life in adults and adolescents with AD in long-term studies.4,5 In this issue of the BJD, Igarashi et al. report efficacy and safety data for a phase III study investigating nemolizumab in Japanese children (aged 6–12 years) with AD who had inadequately controlled moderate-to-severe pruritus.6 Patients were randomized and received subcutaneous nemolizumab 30 mg every 4 weeks (45 patients) or placebo (44 patients) over 16 weeks alongside emollients and low-potency topical corticosteroids (TCS). The primary efficacy endpoint was change in weekly mean 5-level itch score from baseline to week 16. Secondary endpoints included changes in Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in line with the Harmonising Outcome Measures for Eczema core outcome set for eczema.7
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
ORCID-Profile: Antonia Lloyd-Lavery
Zitieren
APA
Lloyd-Lavery, A. (2023). Nemolizumab to target the itch–scratch cycle in paediatric atopic dermatitis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad319
Vancouver
Lloyd-Lavery A. Nemolizumab to target the itch–scratch cycle in paediatric atopic dermatitis. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad319
BibTeX
@article{LloydLavery2023,
author = {Lloyd-Lavery, Antonia},
title = {Nemolizumab to target the itch–scratch cycle in paediatric atopic dermatitis},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad319}
}
EUVIMED